CXCL17 and ICAM2 Are Associated With a Potential Anti-Tumor Immune Response in Early Intraepithelial Stages of Human Pancreatic Carcinogenesis
- 31 January 2011
- journal article
- Published by Elsevier BV in Gastroenterology
- Vol. 140 (1), 310-321.e4
- https://doi.org/10.1053/j.gastro.2010.10.009
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1Proceedings of the National Academy of Sciences of the United States of America, 2009
- Adenylate cyclase-associated protein 1 overexpressed in pancreatic cancers is involved in cancer cell motilityLaboratory Investigation, 2009
- Epithelial ICAM‐1 and ICAM‐2 regulate the egression of human T cells across the bronchial epitheliumThe FASEB Journal, 2008
- Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinomaJournal of Hepatology, 2008
- Getting to the site of inflammation: the leukocyte adhesion cascade updatedNature Reviews Immunology, 2007
- Immune surveillance of tumorsJCI Insight, 2007
- In vivo antigen delivery by aSalmonella typhimurium type III secretion system for therapeutic cancer vaccinesJCI Insight, 2006
- Mechanisms and functional significance of tumour-induced dendritic-cell defectsNature Reviews Immunology, 2004
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004
- Transforming Growth Factor β1, in the Presence of Granulocyte/Macrophage Colony-stimulating Factor and Interleukin 4, Induces Differentiation of Human Peripheral Blood Monocytes into Dendritic Langerhans CellsThe Journal of Experimental Medicine, 1998